About three years after splitting from Versant Ventures’ discovery group, Pipeline Therapeutics has landed an $80 million Series C round to go “much broader” than the Roche-partnered program that birthed it.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,